AMGN
T2Amgen Inc.
GLP-1 Long '24: GLP1 Drug ProducerMedTech Short '25: Heavy China ExposureSmall Themes '25: Ghost Nations
Loading chart…
OverviewAmgen Inc. is a global biotechnology company that discovers, develops, and delivers innovative human medicines and biosimilars for serious illnesses like cancer
Amgen Inc. is a global biotechnology company that discovers, develops, and delivers innovative human medicines and biosimilars for serious illnesses like cancer, heart disease, and inflammatory conditions. Its six key growth drivers represented nearly 70% of Q2 2026 product sales. Amgen primarily sells to healthcare providers, hospitals, pharmacies, and through distributors, with increasing direct-to-patient access.
Search Keywords Brand Product
- MariTide
- Olpasiran
- Repatha
- EVENITY
- TEZSPIRE
- UPLIZNA
- IMDELLTRA
- Xaluritamig
- Dazodalibep
- PAVBLU
- TEPEZZA
- Prolia
- XGEVA
- BLINCYTO
- biotechnology company
- GLP-1 drug
- obesity treatment
- cardiovascular disease therapy
- rare disease medicine
- oncology drug
- biosimilar development
Search Keywords Event Phrases
- Amgen Q2 earnings 2026
- MariTide Phase 3 results
- Olpasiran Phase 3 results
- Xaluritamig Phase 3 results
Search Keywords Policy Regulatory
- Medicare GLP-1 coverage
- FDA approval GLP-1
- drug pricing reform
- What They Do (Plain English & Analogies)
- Amgen is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative human medicines for people with serious illnesses. Think of them as a highly specialized research and development lab that creates complex biological drugs, often made from living cells, to target specific problems in the body. They focus on critical areas like cancer, heart disease, bone problems, inflammatory conditions, and rare diseases where existing treatments are insufficient. Beyond developing new medicines, they also produce high-quality, more affordable versions of existing biological drugs, called biosimilars, to make important treatments accessible to more patients. They handle the entire process from scientific discovery and rigorous testing to large-scale manufacturing and global distribution to healthcare providers and patients.
- Very Brief History
- Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Over the decades, it has grown into a global biotechnology leader, consistently focusing on discovering, developing, manufacturing, and delivering human therapeutics across various therapeutic areas. Key milestones include the launch of numerous blockbuster drugs, continuous investment in a robust pipeline of innovative therapies and biosimilars, and strategic acquisitions like ChemoCentryx in 2022 and Horizon Therapeutics in 2023. The company has expanded its global reach and continues to evolve through strategic collaborations and significant R&D investments.
- "Street Stereotype"
- Amgen is generally perceived by investors and analysts as a mature, large-cap biotechnology company with a strong, diversified portfolio of established blockbuster drugs and a significant presence in biosimilars, providing stable cash flow. However, it's also seen as a company with a promising late-stage pipeline, particularly in high-growth areas like obesity (with MariTide) and cardiovascular disease (with Olpasiran), which could drive future growth. There's an awareness of the ongoing challenge of biosimilar competition for some of its older, high-revenue products, necessitating continuous innovation and pipeline success to offset potential revenue erosion. The market is currently focused on the execution of its 'springboard year' objectives for 2026, driven by its key growth products and pipeline advancements, especially MariTide.
- Subsidiaries On Linked In*
- Amgen Canada Inc. — LinkedIn: Amgen-Canada
- Amgen Fremont Inc.
- Amgen Global Finance B.V.
- Amgen International Holdings Inc.
- Amgen K.K. — LinkedIn: Amgen-K.K.
- Amgen K-A, Inc.
- Amgen Mexico, S.A. de C.V. — LinkedIn: Amgen-Mexico
- Amgen Rare Disease Holdings Inc.
- Amgen S.A.S. — LinkedIn: Amgen-France
- Amgen S.p.A. — LinkedIn: Amgen-Italy
- Amgen Singapore Holding Pte. Ltd.
- Amgen Singapore Manufacturing Pte. Ltd.
- Amgen USA Inc.
- Amgen Worldwide Holdings B.V.
- Amgen, S.A. — LinkedIn: Amgen-Spain
- ChemoCentryx, Inc. — Acquired by Amgen in 2022, maker of Tavneos; LinkedIn: ChemoCentryx
- Five Prime Therapeutics, Inc. — Acquired by Amgen in 2021; LinkedIn: Five-Prime-Therapeutics
- Horizon Therapeutics USA, Inc. — Acquired by Amgen in 2023; LinkedIn: Horizon-Therapeutics
- Onyx Pharmaceuticals, Inc. — Acquired by Amgen; LinkedIn: Onyx-Pharmaceuticals
- deCODE Genetics ehf — LinkedIn: deCODE-genetics
- Viela Bio, Inc. — Acquired by Amgen in 2021; LinkedIn: Viela-Bio
- Customer Sectors & Example Clients
- Amgen primarily serves healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. They also distribute through pharmaceutical wholesale distributors. Based on their business model and industry, example clients would include large healthcare systems (e.g., Kaiser Permanente), pharmacy benefit managers (e.g., CVS Health, Express Scripts), and various hospital networks. They are also expanding direct-to-consumer channels for certain products.
- New Customers / Segments They'Re Targeting
- Amgen is actively targeting several new customer segments and expanding its reach for existing products. For Repatha, they are focusing on increasing adoption among primary care physicians, particularly for high-risk primary prevention patients, including those with diabetes, leveraging the VESALIUS-CV data. For EVENITY, they aim to reach more of the approximately 2 million women in the U.S. at very high risk of fracture who are currently untreated. TEZSPIRE is expanding its impact beyond severe asthma to patients with chronic rhinosinusitis with nasal polyps, and is also improving access through expanded Medicare coverage and self-administration options. UPLIZNA is targeting market leadership in generalized myasthenia gravis (gMG) and is expanding into new indications like autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy. IMDELLTRA is being advanced into earlier treatment lines for small cell lung cancer, aiming to reach as many as 28,000 addressable patients in the U.S. MariTide is being developed to offer a differentiated, less frequent dosing option for obesity and related chronic diseases, including diabetes, heart failure, and ASCVD, potentially attracting patients dissatisfied with weekly GLP-1 therapies.
- Supply Chain And Sourcing Geographies
- Amgen's supply chain involves significant manufacturing operations within the United States, including sites in North Carolina, Ohio, and Puerto Rico. The company also has manufacturing facilities in Ireland, the Netherlands, and Singapore. Amgen made substantial capital expenditures of $500 million in Q2 2026, and expects approximately $2.6 billion in 2026, reflecting significant investment to scale manufacturing capacity for volume growth, including for MariTide's launch. These investments support their leadership in high-quality, world-class biologics manufacturing at scale.
- Sales Geographies And Expansion Plans
- Amgen currently sells its products worldwide. Specific geographies mentioned in the transcript include the U.S. and Japan, where products like EVENITY hold category leadership. The company is actively pursuing global expansion for several products. TEPEZZA is now launched in 13 countries around the world with an additional 6 planned in the coming months. International performance for BLINCYTO was led by broader first-line adoption and strong demand across Europe and Japan. UPLIZNA is seeing sustained momentum across all three approved indications globally. Amgen's biosimilar portfolio supports reliable supply for patients around the world.
- How Key Themes May Help/Hurt
- The 'GLP-1 Drug Producer' theme significantly benefits Amgen due to its late-stage obesity asset, MariTide. MariTide's differentiated profile, offering monthly or less frequent dosing (as few as 4 or 6 doses per year) with strong efficacy and favorable tolerability, aligns perfectly with the bullish trend of increasing patient compliance and market penetration for GLP-1 drugs. This could unlock a 'mass market' for obesity treatment by addressing patient dissatisfaction with weekly injectables. The ongoing expansion of GLP-1 indications beyond weight loss to conditions like diabetes, heart failure, and ASCVD further boosts MariTide's potential market growth and revenue streams, leveraging Amgen's comprehensive cardiovascular risk reduction franchise. While the theme highlights potential competition, MariTide's unique antibody-peptide conjugate design and extended dosing schedule provide a strong competitive advantage. Amgen's investment in scaling manufacturing capacity for MariTide's launch also demonstrates its commitment to capitalizing on this theme.
3 Main Long-Term Bull Details
- Amgen's late-stage pipeline, particularly MariTide for obesity and related chronic diseases, represents a potential paradigm shift with its differentiated profile of strong efficacy, favorable tolerability with a simple 3-step dose escalation, and convenient monthly or less frequent dosing (as few as 4 or 6 doses per year), positioning it for significant long-term market adoption and a multi-billion dollar franchise.
- The company's diversified portfolio of six key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars portfolios) continues to deliver robust performance, collectively generating nearly 70% of sales and growing 26% year-over-year in Q2 2026, effectively offsetting patent expirations and underpinning sustained revenue expansion.
- Amgen is strategically leveraging artificial intelligence and data science across its entire enterprise, from discovery through development and manufacturing, to improve insight, speed, and decision quality, enhancing long-term innovation, operational efficiency, and competitive advantage.
3 Main Long-Term Bear Details
- Amgen anticipates accelerated sales erosion for key products like Prolia and Xgeva, which combined saw a 33% year-over-year decrease in Q2 2026, driven by increased competition from multiple biosimilars, necessitating continuous pipeline success to replace lost revenue.
- Regulatory and pipeline risks persist, as evidenced by the decision to stop development of AMG 513, underscoring the inherent uncertainties and potential setbacks in drug development, even with a robust pipeline.
- Amgen faces substantial financial risk from ongoing tax litigation with the IRS for 2010-2015 and a new draft notice of proposed adjustment for 2016-2018, primarily related to profit allocation with Puerto Rico, which could result in material negative financial adjustments if not resolved favorably.
- Competitors And Differentiation
- Amgen faces competition across its diverse portfolio. For Repatha, while new oral PCSK9 inhibitors like Merck's have been approved, Amgen differentiates Repatha by its unrivaled clinical evidence, including Phase III outcomes data in both primary and secondary prevention, and its established real-world experience. They emphasize that Repatha is the only PCSK9 inhibitor with such comprehensive data and that new entrants are treating other patients rather than directly competing for Repatha's share. In the obesity market, MariTide aims to differentiate itself from other GLP-1 therapies by offering a unique monthly or less frequent dosing schedule (as few as 4 or 6 doses per year) with sustained efficacy and favorable tolerability, addressing patient adherence and persistence challenges. For Prolia and XGEVA, Amgen is experiencing accelerated sales erosion due to increased competition from multiple biosimilars. In the Lp(a) space, Olpasiran is positioned as potentially best-in-class due to its ability to deliver greater than 95% reduction in Lp(a) levels with quarterly dosing, compared to competitors with lower reduction rates and different study designs. Otezla faces competition from new entrants in the dermatology market, but Amgen notes that Otezla is generally used as a first-stop systemic agent, with new entrants competing with each other after Otezla has been tried. Amgen's overall differentiation strategy relies on its deep biologics expertise, global manufacturing scale, and commercial capabilities, which support reliable supply and a strong track record of quality.
- Recent Performance & What The Market'S Focused On
- Amgen reported strong second-quarter 2026 results, with total revenues exceeding $10 billion, a 10% year-over-year increase. Notably, 22 products delivered double-digit sales growth, and 17 products annualized at more than $1 billion based on Q2 sales. The company's six key growth drivers grew at an aggregate rate of 26% year-over-year and represented nearly 70% of Q2 product sales. This strong performance led Amgen to raise its 2026 guidance ranges for both revenue to $38.2 billion to $39.4 billion and non-GAAP earnings per share to between $22.30 and $23.50. The market is focused on the continued momentum of these growth drivers, the progress of late-stage pipeline assets like MariTide, Olpasiran, and Xaluritamig, and the company's ability to successfully navigate biosimilar competition for older products while maintaining strong operating margins and investing in future growth.
- Revenue Segments And Estimated Mix
- 6 Key Growth Drivers (Aggregate) — Mix: ~66.1%; Source: Q2 2026 earnings call, $6.608 billion out of $10 billion total product sales.; Trend: Grew 26% year-over-year in Q2 2026.
- Innovative Oncology Portfolio — Mix: ~20.0%; Source: Q2 2026 earnings call, ~$2 billion out of $10 billion total product sales.; Trend: Grew 18% year-over-year in Q2 2026.
- Rare Disease Portfolio — Mix: ~16.0%; Source: Q2 2026 earnings call, $1.6 billion out of $10 billion total product sales.; Trend: Grew 21% year-over-year in Q2 2026.
- Prolia and XGEVA (combined) — Mix: ~11.0%; Source: Q2 2026 earnings call, $1.1 billion out of $10 billion total product sales.; Trend: Decreased 33% year-over-year in Q2 2026; in line with expectations given biosimilar launches.
- Repatha — Mix: ~9.5%; Source: Q2 2026 earnings call, $953 million out of $10 billion total product sales.; Trend: Grew 37% year-over-year in Q2 2026.
- Biosimilars Portfolio — Mix: ~8.6%; Source: Q2 2026 earnings call, $855 million out of $10 billion total product sales.; Trend: Grew 29% year-over-year in Q2 2026.
- EVENITY — Mix: ~7.1%; Source: Q2 2026 earnings call, $714 million out of $10 billion total product sales.; Trend: Increased 38% in Q2 2026.
- TEPEZZA — Mix: ~5.8%; Source: Q2 2026 earnings call, $576 million out of $10 billion total product sales.; Trend: Grew 14% year-over-year in Q2 2026.
- TEZSPIRE — Mix: ~4.9%; Source: Q2 2026 earnings call, $486 million out of $10 billion total product sales.; Trend: Grew 42% year-over-year in Q2 2026.
- BLINCYTO — Mix: ~4.7%; Source: Q2 2026 earnings call, $472 million out of $10 billion total product sales.; Trend: Increased 23% year-over-year in Q2 2026.
- UPLIZNA — Mix: ~3.4%; Source: Q2 2026 earnings call, $335 million out of $10 billion total product sales.; Trend: Increased 90% year-over-year in Q2 2026.
- PAVBLU — Mix: ~2.9%; Source: Q2 2026 earnings call, $287 million out of $10 billion total product sales.; Trend: Increased 121% year-over-year in Q2 2026.
- IMDELLTRA — Mix: ~2.9%; Source: Q2 2026 earnings call, $288 million out of $10 billion total product sales.; Trend: Increased 115% year-over-year in Q2 2026.
- Otezla — Mix: n/m; Source: Q2 2026 earnings call, volume holding up, price pressure.; Trend: n/m
- TAVNEOS — Mix: n/m; Source: Not mentioned with Q2 2026 sales in transcript.; Trend: n/m
- Product Brands
- Repatha
- EVENITY
- TEZSPIRE
- UPLIZNA
- IMDELLTRA
- MariTide
- Olpasiran
- Xaluritamig
- Prolia
- XGEVA
- TEPEZZA
- Otezla
- BLINCYTO
- PAVBLU
- Enbrel
- Neulasta
- Aranesp
- KYPROLIS
- Nplate
- Vectibix
- MVASI
- Parsabiv
- EPOGEN
- KANJINTI
- Aimovig
- AMGEVITATM
- Sensipar/Mimpara
- NEUPOGEN
- IMLYGIC
- Corlanor
- AVSOLA
- Dazodalibep
Bull / Bear DetailsAmgen Inc. demonstrates robust growth, driven by a diversified portfolio and a rapidly advancing pipeline, notably MariTide for obesity and Olpasiran for cardio
Thesis
Amgen Inc. demonstrates robust growth, driven by a diversified portfolio and a rapidly advancing pipeline, notably MariTide for obesity and Olpasiran for cardiovascular disease. Strong Q2 2026 performance and raised full-year guidance signal successful navigation of patent expirations. While biosimilar competition for key products persists, pipeline execution and growth driver momentum underpin a compelling bull case as of 2026-08-12.
Bull case
Amgen's diversified portfolio continues to deliver robust performance, with its six key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars) collectively growing 26% year-over-year in Q2 2026 and representing nearly 70% of sales. This accelerating, broad-based momentum, including significant growth from Repatha, EVENITY, TEZSPIRE, IMDELLTRA, and biosimilars, effectively offsets patent expirations and underpins sustained revenue expansion.
The late-stage pipeline, particularly MariTide, is rapidly advancing with 12 Phase III studies, offering a differentiated monthly or less frequent dosing regimen for obesity and related conditions, aiming for superior long-term persistence. Olpasiran is progressing in two Phase III cardiovascular outcome studies with a strong Lp(a) reduction profile. Additionally, UPLIZNA, IMDELLTRA, and Xaluritamig are advancing, providing multiple future growth catalysts.
Amgen's strategic and increasing investment in technology, data, and artificial intelligence across its value chain, including a new frontier AI laboratory, is accelerating R&D, optimizing manufacturing, and improving decision quality. This integration enhances long-term innovation, operational efficiency, and competitive advantage, supporting the efficient advancement of its promising pipeline.
Bear case
Amgen continues to face accelerated sales erosion for key products like Prolia and Xgeva, which combined saw a 33% year-over-year decrease in Q2 2026, consistent with expectations due to increased biosimilar competition. This ongoing decline, coupled with pricing pressure on Otezla from 340B exposure, necessitates continuous pipeline success to replace lost revenue.
Regulatory and pipeline risks persist, as evidenced by the decision to discontinue development of AMG 513, a Phase I obesity asset, and the Phase II sunakiment study not meeting its primary endpoint, despite plans for Phase III. These setbacks underscore the inherent uncertainties and potential for delays or failures in drug development, impacting future growth prospects.
Amgen faces substantial financial risk from ongoing tax litigation with the IRS for 2010-2015 and a new draft notice of proposed adjustment for 2016-2018. These disputes, primarily related to profit allocation with Puerto Rico, could result in material financial adjustments if not resolved favorably, impacting future earnings and financial flexibility.
Bull / Bear Case
- Bear Case
- Amgen faces significant headwinds from accelerated sales erosion of key mature products like Prolia and Xgeva, which saw a 33% year-over-year decrease in Q2 2026 due to biosimilar competition. This decline, alongside pricing pressure on Otezla, necessitates continuous, substantial pipeline success to replace lost revenue. Regulatory and pipeline risks persist, as evidenced by the discontinuation of AMG 513 and the Phase II sunakiment study not meeting its primary endpoint. Furthermore, the company carries a substantial financial risk from ongoing tax litigation with the IRS for multiple years, which could result in material negative financial adjustments. Amgen also has a high debt-to-equity ratio post-acquisition, adding to financial leverage concerns.
- Bull Case
- Amgen demonstrates robust growth, driven by a diversified portfolio and a rapidly advancing pipeline. Its six key growth drivers, including Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars, collectively grew 26% year-over-year in Q2 2026, representing nearly 70% of total sales. The late-stage pipeline, notably MariTide for obesity and Olpasiran for cardiovascular disease, is progressing rapidly with multiple Phase III studies, offering differentiated profiles and significant market opportunities. The company's strong Q2 2026 performance, with total revenues increasing 10% year-over-year, led to raised full-year guidance for both revenue and non-GAAP EPS. Strategic investments in AI and technology are also enhancing R&D efficiency and competitive advantage.
- More Compelling & Why
- Bear. Amgen's current PEG ratio of 3.90 suggests the stock is modestly overvalued relative to its growth rate, especially considering its recent run-up and trading above analyst consensus targets. The accelerated sales erosion of mature products and significant debt load present tangible risks that outweigh the priced-in pipeline potential. A substantial positive MariTide Phase III readout, leading to significantly higher revenue projections, or a favorable resolution to the IRS tax litigation, would flip my view.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Initial data readouts from MariTide Phase III SWITCH study and long-term maintenance studies | MariTide's differentiated dosing schedule (monthly or less frequent) and potential to switch from weekly GLP-1s could be a game-changer for patient adherence and market share, validating Amgen's long-term growth strategy in obesity. | Announcement of top-line results, efficacy (e.g., change from baseline body weight after 52 weeks in SWITCH study), and tolerability data (e.g., rates of nausea and vomiting with 3-step dose escalation and less frequent maintenance dosing). | Bullish: Positive data demonstrating superior convenience (less frequent dosing, e.g., 4-6 doses/year) with comparable or superior efficacy and tolerability compared to weekly injectables. Bearish: Data showing no significant differentiation in convenience, efficacy, or tolerability, or unexpected safety signals. | Company press releases, scientific conferences (e.g., American Diabetes Association, ObesityWeek), ClinicalTrials.gov. Timing is not specified beyond 'progressing rapidly' and 'ongoing'. | ClinicalTrials.gov: Study status updates for MariTide Phase III trials. Reddit communities (r/loseit, r/diabetes): Patient discussions on GLP-1 efficacy, side effects, and interest in less frequent dosing. | IQVIA/Symphony Health: Prescription trends for competing GLP-1s (Semaglutide, Tirzepatide) to gauge market dynamics. Revelio Labs: Job postings for Amgen's MariTide commercialization team. |
| Progress and data from Olpasiran Phase III outcome studies | Olpasiran targets a genetically defined, independent cardiovascular risk factor (Lp(a)) not addressed by current therapies, positioning it as a potential best-in-class treatment and a significant future growth driver for Amgen's cardiometabolic franchise. | Updates on the progress of the two Phase III outcome studies (OCEAN(a) in primary and secondary prevention), including any interim analyses or timelines for top-line data. Specific focus on 3-point MACE reduction. | Bullish: Positive updates on trial progress, faster-than-expected event accumulation, or early indications of strong efficacy (e.g., from competitor data read-through if favorable, though Amgen highlights differentiation). Bearish: Delays in trial completion, slower-than-expected event rates, or negative read-through from competitor data that raises concerns about the Lp(a) mechanism. | Company press releases, scientific conferences (e.g., AHA Scientific Sessions, ACC Annual Scientific Session), ClinicalTrials.gov. | ClinicalTrials.gov: Study status updates for Olpasiran Phase III trials. Cardiology news sites for updates on Lp(a) research and competitor trials. | KOL (Key Opinion Leader) surveys: Physician sentiment on Lp(a) testing and the potential of Olpasiran. |
| Amgen's achievement of raised 2026 revenue and non-GAAP EPS guidance | Raised guidance indicates management's increased confidence in the company's financial performance, driven by strong product momentum and pipeline progress, which is a key bullish signal for investors. | Future quarterly earnings reports (Q3 2026, Q4 2026) for reported total revenues and non-GAAP EPS against the new full-year guidance ranges of $38.2 billion to $39.4 billion for revenue and $22.30 to $23.50 for non-GAAP EPS. | Bullish: Q3 2026 results and/or updated full-year outlook indicate performance tracking towards or above the upper end of the raised guidance. Bearish: Q3 2026 results or updated outlook suggest performance tracking below the lower end of the raised guidance, or a subsequent guidance reduction. | Company earnings reports and press releases (Q3 2026 earnings call typically late October/early November 2026). | Financial news outlets (e.g., Reuters, Bloomberg), investor relations sections of Amgen's website. | FactSet: Consensus EPS and Revenue Estimates |
| Rate of accelerated sales erosion for Prolia and Xgeva due to increased biosimilar competition | Prolia and Xgeva represent a significant portion of Amgen's legacy revenue. A faster-than-expected decline could negatively impact overall revenue and profitability, challenging the company's ability to offset losses with growth drivers. | Q3 2026 earnings report (expected late October/early November 2026) and subsequent quarterly reports. Monitor year-over-year percentage change and absolute sales decline for Prolia and Xgeva. | Bullish: Prolia and Xgeva combined sales decline less than 33% year-over-year in Q3 2026, indicating better-than-expected management of biosimilar competition. Bearish: Prolia and Xgeva combined sales decline exceeding 33% year-over-year in Q3 2026, leading to a potential downward revision of overall 2026 revenue guidance. | Company earnings reports and press releases (Q3 2026 earnings call). | Industry news (e.g., BioPharma Dive, Fierce Pharma) for reports on biosimilar market share and pricing pressure. | IQVIA/Symphony Health: Prescription and sales data for denosumab biosimilars. |
| Phase III data readouts for Dazodalibep in Sjögren's disease | Positive Phase III results for Dazodalibep would validate Amgen's rare disease pipeline, address a significant unmet medical need for Sjögren's patients, and potentially establish market leadership in this category. | Announcement of top-line results for the two dedicated Phase III studies (systemic and symptomatic disease) in H2 2026, focusing on ESSDAI score for systemic disease and ESSPRI score/patient diary for symptomatic disease. | Bullish: Positive data demonstrating statistically significant improvement in primary endpoints (ESSDAI, ESSPRI/patient diary) with a favorable safety profile. Bearish: Negative or inconclusive data, or unexpected safety signals that could delay or prevent regulatory approval. | Company press releases, scientific conferences (e.g., ACR Convergence), ClinicalTrials.gov. Expected in H2 2026. | ClinicalTrials.gov: Study status updates for Dazodalibep Phase III trials. Medical journals and rheumatology forums for expert opinions. | KOL (Key Opinion Leader) surveys: Sentiment and expectations regarding Dazodalibep's potential. |
Key Reported Metrics, Reratings Triggers & ResultsThis metric is crucial as it represents a significant drag on overall revenue due to accelerated biosimilar competition. Its decline rate directly impacts Amgen
Upcoming print · 2026-11-03
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Prolia and Xgeva Sales | $1.1 billion (-33% y/y decrease) | This metric is crucial as it represents a significant drag on overall revenue due to accelerated biosimilar competition. Its decline rate directly impacts Amgen's ability to achieve its full-year guidance and manage patent expirations. |
| Key Growth Drivers Sales (Aggregate) | 26% y/y growth | This aggregate metric highlights the performance of Amgen's most important and rapidly growing products, demonstrating the company's ability to generate significant revenue from its innovative portfolio and offset declines from mature assets. |
| Total Revenues | 10% | This metric reflects Amgen's overall financial performance and its ability to grow despite competitive pressures and product declines. It indicates the effectiveness of its diversified portfolio and pipeline, and investors will monitor this for alignment with 2026 guidance. |
Last reported · 2026-08-04
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Key Growth Drivers Sales (Aggregate) | 24% | This aggregate metric highlights the performance of Amgen's most important and rapidly growing products, demonstrating the company's ability to generate significant revenue from its innovative portfolio and offset declines from mature assets. | The Key Growth Drivers Sales (Aggregate) metric needs to hit 25% year-over-year growth or higher in Q2 2026. | Achieving 25%+ growth in key drivers validates Amgen's strategy and reinforces confidence in sustained revenue expansion, supporting raised 2026 guidance. This demonstrates effective navigation of competitive pressures, driving upward valuation and a stronger market position. | 26% y/y growth | Yes | Amgen's six key growth drivers collectively grew at an aggregate rate of 26% year-over-year, exceeding the 25% rerating trigger. This strong performance from key products was highlighted by management as a driver of the overall positive results and confidence in future growth. | |
| Prolia and Xgeva Sales | -32% | This metric is crucial as it represents a significant drag on overall revenue due to accelerated biosimilar competition. Its decline rate directly impacts Amgen's ability to achieve its full-year guidance and manage patent expirations. | Prolia and Xgeva combined sales need to show a year-over-year decline of less than 32% in Q2 2026. | A decline less than 32% signals Amgen is better managing biosimilar competition for these key products, alleviating a significant revenue drag. This would support the company's ability to achieve its raised full-year guidance and strengthen the bull case by demonstrating effective patent expiration management. | $1.1 billion (-33% y/y decrease) | No | Combined sales for Prolia and XGEVA decreased by 33% year-over-year, which was a slightly larger decline than the rerating trigger of less than 32%. However, management stated that this decline was 'in line with our expectations given several biosimilar competitors have now launched.' | |
| Total Product Sales | 4% | This metric reflects Amgen's overall financial performance and its ability to grow despite competitive pressures and product declines. It indicates the effectiveness of its diversified portfolio and pipeline, and investors will monitor this for alignment with 2026 guidance. | Amgen Inc. (AMGN) needs to report Q2 2026 Total Product Sales growth of 10% year-over-year or higher. | Achieving 10%+ Total Product Sales growth would demonstrate Amgen's ability to significantly accelerate top-line performance, exceeding elevated analyst expectations. This validates the strength of its key growth drivers and pipeline, particularly MariTide, effectively offsetting biosimilar competition and reinforcing the bull case for sustained long-term growth. | $10 billion (10% y/y increase) | Yes | Amgen reported total revenues exceeding $10 billion, marking a 10% year-over-year increase, which met the rerating trigger. This strong performance contributed to management raising its 2026 guidance ranges for both revenue and non-GAAP earnings per share. | |
Key QuestionsWill the ongoing Phase III studies for MariTide, including the SWITCH study and long-term maintenance studies, confirm its differentiated profile of strong effi
Will the ongoing Phase III studies for MariTide, including the SWITCH study and long-term maintenance studies, confirm its differentiated profile of strong efficacy, favorable tolerability, and convenient monthly or less frequent dosing (e.g., 4-6 doses per year), thereby driving significant market adoption and validating its potential as a 'new paradigm' GLP-1 therapy?
- Question 2
Can Amgen Inc. successfully achieve its raised 2026 revenue and non-GAAP EPS guidance by effectively offsetting the anticipated accelerated sales erosion from Prolia and Xgeva (which saw a 33% YoY decrease in Q2) with sustained strong performance from its 6 key growth drivers and pipeline assets?
- Question 3
What will be the outcome of Amgen's ongoing tax litigation with the IRS for the 2010-2015 tax years and the newly received draft notice of proposed adjustment for 2016-2018, and what will be the material financial impact on the company's financial statements?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Delivering Durable Growth through Portfolio Strength**: Management repeatedly emphasized the breadth and depth of Amgen's portfolio, highlighting 22 products with double-digit sales growth and 17 products annualized at over $1 billion. They expressed confidence in the company's ability to grow through patent expirations and increased competition, aiming for durable growth well into the next decade. 2. **Advancing Late-Stage Pipeline Assets**: A significant focus was placed on the progress of key late-stage pipeline candidates, specifically MariTide, Olpasiran, and Xaluritamig, which are advancing through Phase III development and are seen as crucial for addressing significant unmet medical needs and driving future growth. 3. **Investing in Innovation, Technology, Data, and AI**: Management underscored the importance of increasing investment in innovation, supported by a sound financial structure. They highlighted the strategic application of technology, data, and artificial intelligence to enhance efficiency in drug discovery, development, and manufacturing. | Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Management reported strong second-quarter performance, with total revenues exceeding $10 billion and a 10% year-over-year increase, leading to a raised 2026 guidance for both revenue and non-GAAP earnings per share. The tone was optimistic, emphasizing the robust momentum of Amgen's 6 key growth drivers, which collectively grew 26% year-over-year and represent nearly 70% of product sales. Management highlighted significant progress in the late-stage pipeline, particularly with MariTide, Olpasiran, and Xaluritamig, and underscored strategic investments in technology, data, and artificial intelligence to drive future innovation and efficiency. While acknowledging anticipated sales erosion for Prolia and XGEVA due to biosimilar competition, the company expressed strong confidence in its diversified portfolio and pipeline to deliver durable long-term growth. The call also included a warm farewell to CFO Peter Griffith, reinforcing a sense of smooth transition and continued financial discipline. | Prior Quarter'S Y/Y Growth By SegmentOverall product sales grew 4% year-over-year in Q1 2026, accelerating to 10% in Q2 2026. The 6 key growth drivers grew 24% year-over-year in Q1 2026, accelerating to 26% in Q2 2026. Repatha sales grew 34% year-over-year in Q1 2026, accelerating to 37% in Q2 2026. EVENITY sales increased 27% year-over-year in Q1 2026, accelerating to 38% in Q2 2026. TEZSPIRE sales grew 20% year-over-year in Q1 2026, accelerating to 42% in Q2 2026. Prolia and XGEVA combined sales decreased 32% year-over-year in Q1 2026, with a slightly deeper decline of 33% in Q2 2026. The Rare Disease portfolio grew 25% year-over-year in Q1 2026, decelerating to 21% in Q2 2026. UPLIZNA sales increased 188% year-over-year in Q1 2026, decelerating to 90% in Q2 2026. TEPEZZA sales grew 29% year-over-year in Q1 2026, decelerating to 14% in Q2 2026. The Innovative Oncology portfolio grew 25% year-over-year in Q1 2026, decelerating to 18% in Q2 2026. IMDELLTRA sales were reported at $258 million in Q1 2026 (percentage growth not explicitly stated for Q1), showing strong growth of 115% in Q2 2026. BLINCYTO sales increased 12% year-over-year in Q1 2026, accelerating to 23% in Q2 2026. The Biosimilar portfolio delivered 14% year-over-year growth in Q1 2026, accelerating to 29% in Q2 2026. PAVBLU sales were reported at $280 million in Q1 2026 (percentage growth not explicitly stated for Q1), showing strong growth of 121% in Q2 2026. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Olpasiran (Lp(a)) Trial Design and Competitive Landscape**: Analysts questioned the design of the OCEAN(a) study, particularly the use of a 3-point MACE endpoint and the exclusion of strokes, and how Amgen views competitor Lp(a) data. Management responded that the OCEAN(a) study enrolled 7,297 patients targeting Lp(a) above 200, and the 3-point MACE endpoint was chosen based on analysis indicating a less compelling association of ischemic stroke with Lp(a) elevation. They highlighted Olpasiran's superior Lp(a) reduction (over 95%) compared to competitors and distinct study design. 2. **MariTide's Tolerability and Dosing Differentiation**: Analysts inquired about the confidence in achieving mid-20s or better vomiting rates in MariTide's Phase III trials and the implications of its unique antibody-peptide conjugate construct for duration of efficacy and real-world dosing flexibility. Management expressed strong confidence in MariTide's profile and the Phase III program. They explained that the antibody design provides a persistent half-life of approximately 21 days for the intact molecule, ensuring sustained GLP-1 agonism and GIP receptor antagonism, which supports less frequent dosing (as few as 4 or 6 doses per year) and offers significant flexibility for patients. 3. **IMDELLTRA's Monitoring Requirements and Expansion into Earlier Lines**: Analysts asked about Amgen's efforts to reduce monitoring requirements for IMDELLTRA and its potential expansion into earlier lines of therapy. Management stated that real-world experience and ongoing clinical studies have shown that monitoring can be reduced from 16 hours to 1-2 hours, especially since neurological consequences (ICANS) are infrequent and predominantly observed at higher doses. They are actively pursuing sequential reductions in monitoring through prospective clinical investigation and engagement with global regulators, while also advancing IMDELLTRA into frontline extensive-stage small cell lung cancer with three Phase III studies. | Revenue SegmentsTotal revenues increased 10% year-over-year. The 6 key growth drivers (Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, Biosimilars) grew at an aggregate rate of 26% year-over-year. Repatha sales grew 37% year-over-year. EVENITY sales increased 38% year-over-year. TEZSPIRE sales grew 42% year-over-year. Prolia and XGEVA combined sales decreased 33% year-over-year. The Rare Disease portfolio grew 21% year-over-year. UPLIZNA sales increased 90% year-over-year. TEPEZZA sales grew 14% year-over-year. The Innovative Oncology portfolio grew 18% year-over-year. IMDELLTRA sales increased 115% year-over-year. BLINCYTO sales increased 23% year-over-year. The Biosimilar portfolio delivered 29% year-over-year growth. PAVBLU sales increased 121% year-over-year. |
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Achieving 2026 objectives as a 'springboard year'**: Management emphasized that 2026 is a year where rapidly growing products are expected to offset patent expirations and increased competition, while next-generation molecules progress through the R&D pipeline, setting the stage for sustained long-term growth. 2. **Advancing the MariTide program**: There is a strong focus on disciplined data generation and execution for MariTide, including new Phase III studies to evaluate switching from weekly injectables to every 8- or 12-week schedules and for weight maintenance, highlighting its potential as a differentiated treatment for obesity and type 2 diabetes. 3. **Leveraging artificial intelligence and data science**: Management is focused on embedding new capabilities across the company by applying AI and data science to accelerate drug discovery, optimize manufacturing processes, improve clinical trial enrollment, and enhance regulatory filing preparation. | Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Management expressed satisfaction with a strong first quarter performance, reinforcing their outlook for 2026 as a 'springboard year' for future growth. They highlighted the robust momentum of their 6 key growth drivers, which collectively generated 70% of sales and grew 24% year-over-year. A significant theme was the advancement of the MariTide program, with new Phase III studies announced to evaluate switching from weekly injectables and long-term maintenance, emphasizing its differentiated profile. Management also underscored the increasing importance and successful integration of artificial intelligence and data science across R&D and operations. The tone was optimistic, with management raising 2026 guidance for both revenue and non-GAAP earnings per share, indicating confidence in their ability to grow through a period of patent expiration and deliver attractive performance. | Prior Quarter'S Y/Y Growth By SegmentOverall sales growth was 10% year-over-year in Q4 2025, decelerating to 4% in Q1 2026. Repatha sales grew 36% year-over-year in Q4 2025, decelerating to 34% in Q1 2026. EVENITY sales grew 34% year-over-year in Q4 2025, decelerating to 27% in Q1 2026. TEZSPIRE sales grew 52% year-over-year in Q4 2025, decelerating to 20% in Q1 2026. Prolia sales increased 1% year-over-year in Q4 2025, significantly decelerating to a 32% decrease (combined with Xgeva) in Q1 2026. The rare disease portfolio sales grew 19% year-over-year in Q4 2025, accelerating to 25% in Q1 2026. UPLIZNA sales grew 73% year-over-year in Q4 2025, significantly accelerating to 188% in Q1 2026. TEPEZZA sales grew 3% year-over-year in Q4 2025, significantly accelerating to 29% in Q1 2026. TAVNEOS sales grew 62% year-over-year in Q4 2025, decelerating to 32% in Q1 2026. The innovative oncology portfolio sales grew 11% year-over-year in Q4 2025, accelerating to 25% in Q1 2026. BLINCYTO sales grew 28% year-over-year in Q4 2025, decelerating to 12% in Q1 2026. The biosimilar portfolio sales grew 37% year-over-year in Q4 2025, decelerating to 14% in Q1 2026. Year-over-year growth for IMDELLTRA and PAVBLU was not explicitly stated for Q4 2025 in percentage terms, making a direct comparison difficult. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **MariTide SWITCH studies design and maintenance opportunity**: Analysts inquired about the design of the MariTide SWITCH studies, specifically the dosing frequencies (monthly, every 2 months, every 3 months) and whether they are looking for superiority or non-inferiority, as well as the significance of the maintenance opportunity. Management responded that the SWITCH study will have 300 subjects with obesity or overweight, with a run-in on weekly semaglutide or tirzepatide, then switching to MariTide every 8-week or quarterly. The primary endpoint will be change from baseline body weight after 52 weeks. They also highlighted the importance of understanding how to convert from weekly agents to a more convenient regimen and how to modify the dose interval for maintenance. 2. **IMDELLTRA's future in earlier lines of therapy and the real-time clinical trial pilot program**: Analysts asked about the next steps for IMDELLTRA, particularly its opportunity in earlier lines of therapy and its selection for the real-time clinical trial pilot program. Management stated that IMDELLTRA is being advanced into frontline induction as well as frontline induction and maintenance in extensive-stage small cell lung cancer, with studies rapidly progressing. Regarding the real-time clinical trial, they explained it's a collaboration with the FDA to characterize IMDELLTRA in a real-world setting using electronic health records and real-time data capture, aiming to improve trial efficiency and patient access. 3. **Olpasiran's trial design and the impact of background therapies (GLP-1 or PCSK9)**: Analysts questioned whether background therapies like GLP-1s or PCSK9s would impact Olpasiran's trial design or competitor trial designs. Management affirmed the well-designed OCEAN(a) study for high-risk Lp(a) patients, noting that Olpasiran delivers greater than 95% reduction in Lp(a) with quarterly dosing. They emphasized that GLP-1 medicines, statins, or Repatha (PCSK9) do not meaningfully reduce Lp(a) levels, making Olpasiran's targeted therapy crucial for this independent risk factor. | Revenue SegmentsOverall product sales grew 4% year-over-year. The 6 key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars portfolios) collectively delivered 24% year-over-year sales growth. Repatha sales increased 34% year-over-year. EVENITY sales increased 27% year-over-year. TEZSPIRE sales grew 20% year-over-year. Prolia and XGEVA combined sales decreased 32% year-over-year. The rare disease portfolio grew 25% year-over-year. UPLIZNA sales increased 188% year-over-year. TEPEZZA sales grew 29% year-over-year. TAVNEOS sales were up 32% year-over-year. The innovative oncology portfolio grew 25% year-over-year. IMDELLTRA delivered $258 million in first quarter sales. BLINCYTO sales increased 12% year-over-year. The biosimilar portfolio delivered 14% year-over-year growth. PAVBLU delivered $280 million in first quarter sales. |
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Driving growth from key products and pipeline: Management highlighted 14 products achieving blockbuster status, 13 with double-digit growth, and 18 achieving record results in 2025. They specifically called out Repatha, Evenity, and TestSpire as growing over 30% year-over-year and being "growth drivers not just for 2026, but for the rest of the decade." They also emphasized the rare disease, innovative oncology, and biosimilars portfolios. 2. Advancing a robust and differentiated pipeline, especially Meritide and opaziran: Management expressed strong confidence in Meritide for obesity, type 2 diabetes, and related conditions, emphasizing its potential for strong efficacy, favorable tolerability, and infrequent dosing (monthly, bimonthly, or quarterly). They also highlighted opaziran for elevated Lp(a) as an opportunity to expand leadership in cardiometabolic disease. 3. Disciplined execution, data generation, and financial discipline: Management repeatedly mentioned "strong disciplined execution across R&D" and "disciplined data generation" for 2026. Peter Griffith also underscored "rigorous management of working capital" and "maintaining rigorous financial discipline," while investing in the business and returning capital to shareholders. | Call Takeaway & ToneThe call conveyed a positive and confident tone. Management highlighted strong operational performance in 2025, with double-digit revenue and EPS growth, and expressed excitement about carrying this momentum into 2026. Key takeaways included the robust performance of established growth drivers (Repatha, Evenity, TestSpire), the significant potential of the late-stage pipeline, particularly Meritide for obesity and diabetes, and opaziran for cardiovascular disease, and the continued strength of their rare disease, innovative oncology, and biosimilars portfolios. Management emphasized disciplined execution, data generation, and financial rigor. While analysts pressed on competitive landscapes and pipeline specifics, management's responses consistently reinforced their strong market position, differentiated assets, and confidence in future growth. | Prior Quarter'S Y/Y Growth By SegmentOverall revenues: 12% year over year. Repatha: 40% year over year. EVENITY: 36% year over year. TEZSPIRE: 40% year over year. TEPEZZA: 15% year over year. UPLIZNA (EPLISMA): 46% year over year. TAVNEOS (TADNIA): 34% year over year. Biosimilar portfolio: 52% year over year. BLINCYTO: Double-digit growth (specific percentage not found). Prolia: No specific y/y growth percentage found for Q3 2025. Innovative oncology portfolio: Not explicitly stated as a combined segment, but Imdeltra had 33% sequential growth. Otezla: An intangible asset impairment charge of $400 million was recorded in Q3 2025, no y/y growth percentage found. Rare disease portfolio: Not explicitly stated as a combined segment, but individual rare disease products like Uplizna showed strong growth. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. Meritide's potential and dosing frequency (and the broader obesity portfolio): Analysts inquired about Amgen's overall obesity portfolio and the potential for Meritide's less frequent than monthly dosing. Management responded by emphasizing Meritide's potential as a "paradigm-changing therapy" with strong efficacy, good tolerability, and the ability to offer monthly, every eight-week, or quarterly dosing for maintenance, which they believe addresses a major unmet need and patient dissatisfaction with weekly GLP-1s. They also mentioned other clinical and preclinical assets in their obesity pipeline. 2. Aplisna's market opportunity and expansion into new indications (IgG4-related disease and gMG): Analysts asked about the size of the IgG4-related disease population and Aplisna's early uptake and role in the crowded generalized myasthenia gravis (gMG) market. Management acknowledged the evolving understanding of the IgG4-related disease epidemiology and expressed satisfaction with Aplisna's strong uptake across specialties. For gMG, they noted strong early interest from both bio-naive and switch patients, highlighting its upstream B-cell mechanism, safety profile, and twice-yearly dosing convenience as key differentiators. They also discussed the rationale for expanding Aplisna into autoimmune hepatitis and CIDP based on its mechanism. 3. Repatha's strategy amidst potential new PCSK9 competitors (like Merck's oral PCSK9): Analysts questioned how Amgen plans to maintain Repatha's leadership, especially with the potential launch of oral PCSK9 inhibitors, and the evolving role of primary care in prescribing. Management stressed the "landmark data" from the Vesalius CV trial, which demonstrated Repatha's ability to reduce the risk of first major cardiovascular events in high-risk primary and secondary prevention patients. They asserted that Repatha is the "most evidence-backed therapy in the PCSK9 class" and that new competitors "will not have the data package and profile that Repatha has established." They also noted that while primary prevention prescriptions were around 40%, they expect this to grow, with strong interest from both cardiologists and primary care physicians in the Vesalius data. | Revenue SegmentsOverall sales growth: 10% year over year. Repatha sales: 36% year over year. Evenity sales: 34% year over year. Rare disease portfolio sales: 14% year over year (full year), 19% (Q4). EPLISMA sales: 73% year over year. TEPEZZA sales: 3% year over year. TADNIA sales: 62% year over year. TestBio (TESSPIRE) sales: 52% year over year. Otezla sales: 7% year over year. Innovative oncology portfolio sales: 11% year over year. BLINCYTO sales: 28% year over year. Biosimilar portfolio sales: 37% year over year. Prolia sales: 1% year over year. Imdeltro full-year sales: $627 million (y/y growth not specified). PAV Blue 2025 sales: $700 million (y/y growth not specified). |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAmgen expects to reach more patients with innovative medicines and biosimilars in the second half of 2026 than ever before, driven by volume demand. The company is investing in expanding the long-term potential of its products by adding indications, broadening geographic reach, improving dosage administration, and expanding payer access. Repatha, for example, has broad access and is uniquely positioned to close the treatment gap for the estimated 100 million patients worldwide still above their LDL-C goals. EVENITY has a significant opportunity in the U.S. with approximately 2 million women at very high risk of fracture and only mid-single-digit penetration to date. TEZSPIRE is expanding its impact through expanded Medicare access and uptake in chronic rhinosinusitis with nasal polyps, with additional indications expected. UPLIZNA is seeing sustained momentum across its three approved indications and is initiating registrational studies in autoimmune hepatitis (affecting 150,000 U.S. patients) and chronic inflammatory demyelinating polyneuropathy (affecting 35,000 U.S. patients). TEPEZZA is launched in 13 countries globally with 6 more planned, and a subcutaneous on-body injector is advancing to enhance convenience and enable more sites of care. IMDELLTRA aims to further penetrate the second-line small cell lung cancer population and is advancing into first-line extensive stage, with potential to reach 28,000 addressable patients in the U.S. Olpasiran is advancing into two Phase III outcome studies for both primary and secondary prevention of cardiovascular disease. MariTide is progressing with 9 ongoing and 3 additional planned Phase III studies across obesity and related chronic diseases, including evaluating switching from weekly GLP-1 therapies to MariTide's less frequent dosing. Dazodalibep is being studied in both systemic and symptomatic Sjögren's disease populations due to significant unmet need. | About CompetitionAmgen expects to grow through patent expirations and increased competition. Prolia and XGEVA sales decreased 33% year-over-year, which is in line with expectations due to the launch of several biosimilar competitors. Repatha is highlighted as having unrivaled clinical evidence in its class, being the only PCSK9 inhibitor with Phase III outcomes data in both primary and secondary prevention, and its data are considered superior to newly approved oral PCSK9 inhibitors, which have different label language and potential compliance challenges. For Lp(a), Amgen believes Olpasiran has superior properties with a 95% Lp(a) reduction compared to a competitor's 70%, and differences in study design. Otezla is not seeing direct competition from new entrants, as they compete with each other after Otezla has been tried, though Otezla is experiencing some price pressure due to 340B exposure. MariTide is positioned as fundamentally different from other GLP-1 therapies, designed for monthly or less frequent dosing, and aims to enable patients to switch from weekly GLP-1s to a less frequent maintenance schedule. | About The Broader IndustryThe company notes that it is delivering a level of consistent, compelling performance that is rarely seen in the industry. There is also an observation of 'some exciting early-stage progress in our industry right now'. The broader industry is experiencing a 'convergence of technology and life science,' with significant advancements in artificial intelligence being applied across Amgen's value chain to accelerate drug discovery, development, manufacturing, and improve insight, speed, and decision quality. The next chapter in obesity treatment is not simply greater weight loss, but achieving long-term persistent benefit. | Where Things Are HeadedAmgen is confident in its ability to deliver durable growth well into the next decade, expecting to reach more patients with innovative medicines and biosimilars in the second half of 2026 than ever before. The company's strategy focuses on disciplined execution, generating high-quality evidence for its late-stage pipeline, and investing in technology, data, and artificial intelligence to advance medicines more efficiently. MariTide aims to be the first monthly or less frequent obesity therapy, making long-term treatment easier for patients. Amgen plans to continue expanding its bispecific T cell engager (BiTE) platform across tumor types and earlier lines of treatment. The company is raising its 2026 guidance ranges for total revenues to $38.2 billion to $39.4 billion and non-GAAP earnings per share to between $22.30 and $23.50. Full-year non-GAAP R&D expense is expected to grow high single digits year-over-year, including investments in MariTide, Xaluritamig, and Olpasiran. A meaningful sequential increase in operating expenses is anticipated in the third quarter due to incremental investments in the pipeline and commercial brands. Amgen aims to expand its leadership in serious chronic diseases well into the next decade with its cardiovascular portfolio, including Repatha, Olpasiran, and MariTide. | Updates On ThemeGLP1 | Broader Themes EmergingThe 'convergence of technology and life science' is a significant broader theme, with Amgen strategically applying artificial intelligence (AI) across discovery, development, manufacturing, and access to medicines to improve insight, speed, and decision quality. This includes establishing a frontier AI laboratory that combines advanced models with proprietary data and scientific capabilities, bringing 'agentic workflows' to discovery research to augment scientists' insights. | Bullish-Leaning Quotes (Short)Our strong results were driven by the breadth and depth of our portfolio. Total revenues exceeded $10 billion, a 10% year-over-year increase. We remain confident in our ability to deliver durable growth well into the next decade. MariTide, Olpasiran and Xaluritamig are advancing through Phase III development and have the potential to address areas of significant unmet medical need. We are raising our 2026 guidance ranges for both revenue and non-GAAP earnings per share. | Bearish-Leaning Quotes (Short)Prolia and XGEVA combined delivered $1.1 billion in second quarter sales, a decrease of 33% year-over-year. This is in line with our expectations given several biosimilar competitors have now launched. We have decided to stop development of AMG 513, a Phase I asset. As I've said before, the bar is high at Amgen for obesity medicines. Although the primary endpoint was not statistically significant, we are encouraged by the overall profile and are planning a Phase III program with AstraZeneca. We are seeing definitely some pressure on price with Otezla given some 340B exposure on that product. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAmgen expects to grow through patent expirations and competition by leveraging its portfolio of innovative medicines and biosimilars to meet patient needs. MariTide's Phase III studies are evaluating switching from weekly injectables to an every 8- or 12-week schedule and weight maintenance on a 4 or 6 injections per year schedule, aiming to improve long-term treatment persistence. Repatha's market is expanding due to updated ACC/AHA guidelines reinforcing earlier risk identification and lower LDL-C targets, and a simplified cash pay option in the U.S. EVENITY has a significant opportunity to expand its market as over 90% of 2 million women at very high fracture risk remain untreated. TEZSPIRE's new indication for coexisting chronic rhinosinusitis with nasal polyps is expanding its reach. UPLIZNA is seeing strong uptake in gMG across bio-naive and switch patients, with broad access, and is expected to initiate two pivotal Phase III studies in autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy. TEPEZZA's on-body injector will enable administration at additional sites of care and global launches are planned for 2026 and beyond. IMDELLTRA is expanding patient access through efforts to remove operational barriers in community settings and is being advanced into earlier lines of therapy for small cell lung cancer. Olpasiran's potential market is growing with new ACC/AHA lipid guidelines recommending broader Lp(a) testing. | About CompetitionAmgen anticipates accelerated sales erosion for Prolia and Xgeva over the remainder of 2026 due to increased competition from multiple biosimilars. MariTide aims to differentiate itself from existing obesity medicines by offering less frequent dosing (monthly, every 8- or 12-weeks) and favorable tolerability, addressing treatment burden and persistence issues. Repatha is highlighted as the only PCSK9 inhibitor with positive outcomes data in both high-risk primary and secondary prevention patients. Olpasiran targets Lp(a), an independent risk factor not meaningfully reduced by GLP-1 medicines, statins, or PCSK9 inhibitors. Amgen acknowledges coming later into the GLP-1 market but sees an opportunity to convert patients from weekly agents to MariTide's more convenient regimen, especially for those dissatisfied with current therapies. | About The Broader IndustryThe broader industry is experiencing a 'convergence of technology and biology,' with significant advancements in artificial intelligence being applied across Amgen. This includes leveraging AI to accelerate drug discovery and therapeutic development, optimize manufacturing, and improve customer engagement. Tangible benefits are being seen in integrated multi-omics data resources for target identification, a 50% acceleration in antibody lead optimization, and up to a threefold improvement in clinical trial enrollment rates through proprietary site selection models. Large language models and Agentic AI are showing promising results in regulatory filing preparation, and AI-enabled automation has reduced production line clearance time at a manufacturing site from approximately 30 minutes to about 2 minutes per batch run. | Where Things Are HeadedAmgen describes 2026 as a 'springboard year for future growth,' with rapidly growing products expected to offset patent expirations and increased competition, while next-generation molecules progress through the R&D pipeline for sustained long-term growth. The company's focus for the year is on disciplined data generation and execution across important Phase III programs. MariTide is emerging as a new paradigm for obesity, diabetes, and related conditions, with a focus on high-quality clinical data for future regulatory filings. Amgen is raising its 2026 guidance ranges for total revenues to $37.1 billion to $38.5 billion and non-GAAP earnings per share to between $21.70 and $23.10, reflecting confidence that emerging growth drivers will offset legacy brand declines. The company remains focused on delivering sustained long-term growth, advancing innovation, and maintaining rigorous financial discipline. | Updates On ThemeGLP1 | Broader Themes EmergingThe 'convergence of technology and biology' is a significant broader theme, with Amgen actively integrating artificial intelligence (AI) across its enterprise. This includes AI for accelerating drug discovery and development, optimizing manufacturing processes, and enhancing productivity for colleagues. Specific applications mentioned are multi-omics data resources for target identification, accelerated antibody lead optimization, improved clinical trial enrollment through AI-enabled site selection models, and leveraging large language models and Agentic AI for regulatory filing preparation. AI-enabled automation has also significantly reduced production line clearance time in manufacturing. | Bullish-Leaning Quotes (Short)We had a strong first quarter and are well positioned to achieve our objectives for the year. Our confidence in MariTide as a differentiated treatment for obesity, type 2 diabetes and obesity-related conditions continues to build. Together, they generated 70% of our sales in the quarter and grew in aggregate by 24%. MariTide is emerging as a new paradigm for patients with obesity, diabetes and related conditions as a well-tolerated first monthly or less frequently administered medicine. We're raising our 2026 guidance ranges for both revenue and non-GAAP earnings per share. | Bearish-Leaning Quotes (Short)offset the financial impact of patent expirations and increased competition. Erosion since loss of exclusivity remains in line with our expectations, and we anticipate accelerated sales erosion over the remainder of 2026, driven by increased competition from multiple biosimilars. As publicly disclosed, the FDA proposed to withdraw the approval of TAVNEOS. We've taken the decision to discontinue development of AMG 193. If sustained in full, the adjustments set forth in the draft NOPA could have a material impact on our financial statements. | HiringEVENITY's growth has been supported by an expanded field force. Jay Bradner is taking over the leadership of AI and data transformation across the business at the enterprise level, following the retirement of David Reese, who was Amgen's first Chief Technology Officer and helped attract Jay Bradner. Amgen colleagues are using AI to enhance productivity. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAmgen Inc. sees significant growth opportunities by reaching new patients, expanding into additional geographies, and launching new indications for its rare disease portfolio. Repatha targets over 100 million people globally who still need effective LDL cholesterol lowering, with new data strengthening its position for both high-risk primary and secondary prevention, potentially leading to updated clinical guidelines. Evenity has a clear opportunity for growth as nearly 90% of the 2 million women at very high risk of fracture remain untreated. Uplisna received FDA approval for generalized myasthenia gravis and European Commission approval for IgG4-related disease in 2025, with strong early physician response and growing uptake across various specialties. Meritide is expanding its clinical landscape across obesity-related conditions, including two Phase III sleep apnea studies, and offers the potential for monthly, every other month, or even quarterly dosing. TEPEZZA plans to launch in additional international markets in 2026 and is expanding treatment to lower clinical activity score thyroid eye disease patients. Imdeltra is being advanced as combination therapy in frontline extensive-stage small cell lung cancer and in a Phase III study for limited-stage small cell lung cancer. | About CompetitionAmgen Inc. anticipates accelerated sales erosion for Prolia in 2026 due to increased competition from multiple biosimilars launched globally. Otezla is expected to face sales erosion from unfavorable pricing in the U.S. and generic launches, particularly in the EU. The company acknowledges anticipated declines from increased denosumab biosimilar competition and price declines for certain other products in 2026. Despite new entrants, Amgen Inc. asserts that Repatha will maintain its leadership due to its established data package and profile, which competitors will not have. Meritide is highlighted as standing alone in late-stage development for obesity and type two diabetes, offering strong efficacy and favorable tolerability at less frequent dosing compared to dozens of potential daily oral and weekly injectable medicines. Amgen Inc.'s biosimilars portfolio, which generated $3 billion in sales in 2025, is poised for growth with the next wave of launches, including ABP-206 (Opdivo biosimilar) and ABP-234 (Keytruda biosimilar). PAV Blue, a biosimilar to EYLEA, continues to gain momentum and is competing effectively against the innovator and anticipated future entrants. | About The Broader IndustryThe broader industry is experiencing a significant trend in the 'convergence of technology and life science,' which Amgen Inc. believes will have a substantial impact on how medicines are discovered, developed, and commercialized. Amgen Inc. is leveraging AI across its value chain to accelerate therapeutic discovery and late-stage development, optimize manufacturing, and improve customer engagement, driving productivity at speed and scale. | Where Things Are HeadedAmgen Inc. expects 2026 to be a 'springboard year for future growth,' with anticipated total revenues in the range of $37 billion to $38.4 billion and non-GAAP earnings per share between $21.6 to $23. The company highlights six areas of momentum for 2026, including Repatha, Evenity, and TestSpire, which are expected to be growth drivers for the rest of the decade. Amgen Inc. plans for 2026 to be a year of disciplined data generation from exciting Phase II and Phase III programs. The combination of Repatha, opaziran, and Meritide is seen as a compelling set of cardiometabolic medicines to expand leadership in serious chronic diseases well into the next decade. The company remains focused on delivering sustained long-term growth and creating value for patients and shareholders by advancing innovation in areas of high unmet medical need and maintaining rigorous financial discipline. | Updates On ThemeGLP1 | Broader Themes EmergingThe 'convergence of technology and life science' is a broader theme emerging, with Amgen Inc. actively 'leveraging AI across the value chain to accelerate therapeutic discovery and late-stage development, optimize manufacturing, and improve customer engagement.' | Bullish-Leaning Quotes (Short)Amgen Inc. delivered strong operational performance across the board in 2025. 14 of our products achieved blockbuster status with sales of a billion dollars or more. The strength of that broad portfolio enabled us to post double-digit growth in revenues and earnings per share for 2025. Meritide stands alone as the only therapy in late-stage development to offer the paradigm-changing prospect of strong efficacy and favorable tolerability at monthly, every other month, or even quarterly dosing. We expect our 2026 total revenues in the range of $37 billion to $38.4 billion and non-GAAP earnings per share between $21.6 to $23. positioning 2026 as a springboard year for future growth. | Bearish-Leaning Quotes (Short)In 2026, we expect accelerated sales erosion driven by increased competition as multiple biosimilars have launched globally. For 2026, We expect sales erosion driven by unfavorable pricing in The U.S., and generic launches particularly in The EU. We recently announced the decision to terminate the role rocotinlimab development and commercialization collaboration with Kewa Kirin. We have decided not to pursue regulatory approval for bimirtuzumab. The FDA requested a voluntary withdrawal on January 16. We were surprised by this. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-02-03 | Amgen reported strong Q4 2025 results with double-digit revenue and EPS growth, fueled by key products and an optimistic 2026 outlook. The company highlighted pipeline momentum, particularly for Meritide in obesity. Despite biosimilar competition and a Tavneos withdrawal request, the market reacted very positively, with the stock gaining 13.51% (t+2 days), significantly outperforming the SPY. | Earnings Transcript | Mixed | +13.51% (vs SPY: +13.35%) | |
| 2026-08-04 | Amgen reported strong Q2 2026 results with 10% revenue growth, driven by 26% growth in its six key drivers, and raised full-year guidance. Despite anticipated biosimilar erosion for Prolia/Xgeva, pipeline advancements like MariTide (obesity) and Olpasiran (cardiovascular) fueled optimism. The stock surged 7.64% (t+2 days), significantly outperforming the SPY, indicating strong market confidence in Amgen's durable growth strategy. | Earnings Transcript | Positive | +7.64% (vs SPY: +7.39%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| AMGN_17b91ee0 | study completion expected in 2026. | 2026-07-01 | 2026-12-31 | Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease. | Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition. | Ticker | 2026-02-03 | earnings_transcript |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript |